Clinical trials: Chemotherapy Induced Peripheral Neuropathy (CIPN)
- Condition Chemotherapy Induced Peripheral Neuropathy (CIPN)
- Funder type Industry (pharma, biotech, devices)
Chemotherapy Induced Peripheral Neuropathy (CIPN)
The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study
Chemotherapy drugs, used in the treatment of cancer, have the potential of inducing peripheral neuropathy (PN) as a side effect. This side effect is commonly referred to as CIPN, or chemotherapy-induced peripheral neuropathy.
- Trial name
- IMPACT (NCT07142304)
- Testing
- The Lilac Device
- Where
- 18 sites in United States, Ireland
- Volunteers
- 142 people
- Sponsor
- Luminate Medical, Inc.
Chemotherapy-induced Peripheral Neuropathy (CIPN)
AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AK135 for the treatment of chemotherapy-induced peripheral neuropathy in patients with…
- Trial name
- NCT06860789
- Testing
- AK135
- Where
- 2 sites in China
- Volunteers
- 85 people
- Sponsor
- Akeso
CIPN in Adjuvant Colon Cancer Patients, CIPN in Adjuvant Breast Cancer Patients
Observational STudy to Evaluate the EFfectiveness of OnLife® in Improving CIPN in Patients With Colon or Breast Cancer After End of Adj. Therapy
The objective of this observational study is to evaluate the effectiveness of the dietary supplementation "OnLife" in improving signs and symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in adult patients who have…
- Trial name
- STEFANO (NCT03065478)
- Testing
- OnLife
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Swiss Medical Food AG
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Safety and Efficacy of JMKX000189 for Chemotherapy-Induced Peripheral Neuropathy
This Phase Ib clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of JMKX000189 tablets in participants with chemotherapy-induced peripheral neuropathy (CIPN).
- Trial name
- NCT07601386
- Testing
- JMKX000189
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Jeyou Pharmaceutical Co., Ltd.
Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)
This study evaluates the investigational drug PledOx in the prevention of chronic chemotherapy induced peripheral neuropathy (CIPN) induced by the drug oxaliplatin.
- Trial name
- POLAR-M (NCT03654729)
- Testing
- Calmangafodipir (2 µmol/kg), Calmangafodipir (5 µmol/kg)
- Where
- 98 sites in United States, Belgium and 11 more
- Volunteers
- 291 people
- Sponsor
- Egetis Therapeutics AB (publ)
Chemotherapy-induced Peripheral Neuropathy
A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)
The primary objective of the study is: to assess the safety and tolerability of multiple oral (twice daily [BID]) doses of TRK-750 in oxaliplatin-treated colorectal cancer patients with chemotherapy-induced peripheral neuropathy…
- Trial name
- NCT04282590
- Sponsor
- Toray Industries, Inc
Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer
This study is to evaluate PledOx for prevention of chronic chemotherapy induced peripheral neuropathy induced by oxaliplatin in patients with Stage III or high-risk Stage II colorectal cancer (CRC).
- Trial name
- POLAR-A (NCT04034355)
- Testing
- Calmangafodipir (5 µmol/kg)
- Where
- 65 sites in Belgium, Czechia and 8 more
- Volunteers
- 301 people
- Sponsor
- Egetis Therapeutics AB (publ)
Quality of Life (QOL), CIPN - Chemotherapy-Induced Peripheral Neuropathy
Study for the Evaluation of the Degree of Skin Satisfaction of a Cosmetic Cream for Sensitive Skin in Oncological Patients Affected by a Palmoplantar Polyneuropathy Secondary to Chemotherapy.
It is proposed a controlled research study aimed to evaluating and comparing the degree of skin satisfaction and comfort with cosmetic creams PB-011 and PB-012 in cancer patients who can develop a palmar and plantar peripheral…
- Trial name
- NCT06733545
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- PROSPERA BIOTECH S.L.
Chemotherapy-induced Peripheral Neuropathy (CIPN)
SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)
The study will be conducted in adult patients with Chemotherapy-induced Peripheral Neuropathy (CIPN) that has been persistent for at least 3 months following completion of chemotherapy.
- Trial name
- NCT05435742
- Testing
- SON-080
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- Sonnet BioTherapeutics
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a…
- Trial name
- NCT07697560
- Testing
- AH-008 for Injection, 150 mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
Peripheral Nervous System Diseases
Pre-study to Evaluate IENFD Induction in Patients With Taxane-induced CIPN
This is a non-interventional study examining IENFD levels in patients with CIPN after taxane chemotherapy and in age-matched healthy subjects.
- Trial name
- NCT05133947
- Testing
- Non interventional
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
Peripheral Nervous System Diseases
A Study to Investigate the Safety and Efficacy of Ricolinostat
This is a double-blind, placebo-controlled study during which patients will receive ricolinostat or placebo.
- Trial name
- NCT05229042
- Testing
- Ricolinostat
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
Chemotherapy-induced Peripheral Neuropathy (CIPN)
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
This study is a randomized, double-blind, multicenter, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GM1 in preventing chemotherapy-induced peripheral neuropathy in breast cancer…
- Trial name
- NCT06994507
- Testing
- GM1
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Cancer
A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
A multicenter, phase IV, interventional study to assess the efficacy and safety of Targin (Oxycodone/Naloxone) Korean patients with CIPN (Chemotherapy-Induced Peripheral Neuropathy) who need opioid combination treatment with…
- Trial name
- NCT01675531
- Testing
- Targin
- Where
- South Korea
- Volunteers
- 73 people
- Sponsor
- Mundipharma Korea Ltd
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy
Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy
This is an observational study to discover risk factors of chemotherapy-induced peripheral neuropathy (CIPN) in 350 patients with early stage breast cancer undergoing taxane-based chemotherapy at two main sites (University of…
- Conditions
- Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Aging
- Trial name
- SENSE (NCT04932031)
- Where
- 2 sites in United States
- Volunteers
- 123 people
- Sponsor
- Sapere Bio
Chemotherapy Induced Peripheral Neuropathy, Chemotherapy Induced Peripheral Neuropathy (CIPN)
Helping Cancer Patients Manage Neuropathy Symptoms From Chemotherapy With a Low-Intensity, Low-Risk Cranial PEMF Device
The goal of this clinical trial is to examine a low-intensity, low-risk cranial PEMF device and its effectiveness with helping cancer patients manage neuropathy symptoms from chemotherapy.
- Conditions
- Chemotherapy Induced Peripheral Neuropathy, Chemotherapy Induced Peripheral Neuropathy (CIPN), Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Neuropathic Pain
- Trial name
- NCT07061769
- Testing
- SHIFT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- FluxWear, INC
Chemotherapy-induced Peripheral Neuropathy
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy.
- Trial name
- NCT07765446
- Testing
- SIR2501
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sironax USA, Inc.
Chemotherapy-induced Peripheral Neuropathy
Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
This is a prospective natural history study of CIPN in approximately 200 participants receiving taxanes (paclitaxel, docetaxel) for breast cancer, bortezomib for multiple myeloma, oxaliplatin-based regimens for colorectal cancer…
- Trial name
- EPIPHANY (NCT03997981)
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Disarm Therapeutics
Peripheral Sensory Neuropathy
Clinical Study on Acetyl-L-Carnitine
Chemotherapy-induced peripheral neuropathy (CIPN) is a common clinical dose-limiting adverse drug reaction, and the primary manifestations are different degree of neuromotor, sensorineural and autonomic nervous dysfunction.
- Trial name
- NCT01526564
- Testing
- Acetylcarnitine
- Volunteers
- 239 people
- Sponsor
- Lee's Pharmaceutical Limited
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
To investigate the safety and CIPN onset-suppressing effect of ONO-2910 in participants receiving paclitaxel (PTX) weekly as chemotherapy for breast cancer in Japan.
- Trial name
- NCT06538272
- Testing
- ONO-2910
- Where
- 30 sites in Japan
- Volunteers
- 210 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.